遅発性ジスキネジア治療市場規模、シェア、成長分析、治療別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測 2025年～2032年

遅発性ジスキネジア治療の世界市場規模は2023年に36億米ドルと評価され、2024年の38億8,000万米ドルから2032年には70億8,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.8％で成長する見通しです。

市場情勢は、精神疾患の有病率の上昇とVMAT2阻害剤治療の進歩によって大きく変化しています。早期承認に対する規制当局の支援の高まりは、治療導入に有利な環境を醸成しています。遅発性ジスキネジアに対する認識の高まりは、特にヘルスケアインフラが拡大している地域において、この疾患の積極的な管理を促しています。製薬企業は、研究開発を強化するために戦略的パートナーシップを積極的に推進しています。しかし、市場開発は高い治療費、現在の治療法に伴う副作用、新興国地域での認知度の低さなどの課題に直面しています。さらに、患者数が少ないために研究開発投資が抑制されていることも、将来的に遅発性ジスキネジア治療の普及を妨げる可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

遅発性ジスキネジア治療市場規模：治療別& CAGR（2025-2032）

• 市場概要
• 薬
• 手術

遅発性ジスキネジア治療市場規模：薬物別& CAGR（2025-2032）

• 市場概要
• 抗精神病薬
• VMAT2阻害剤
• ボツリヌス毒素
• 自然療法
• ドーパミン減少薬
• その他

遅発性ジスキネジア治療市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 注射剤

遅発性ジスキネジア治療市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• ホームケア
• 専門クリニック
• その他

遅発性ジスキネジア治療市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• その他

遅発性ジスキネジア治療市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Neurocrine Biosciences, Inc.（U.S.）
• Teva Pharmaceutical Industries Ltd.（Israel）
• H. Lundbeck A/S（Denmark）
• AbbVie Inc.（U.S.）
• Otsuka Holdings Co., Ltd.（Japan）
• Astellas Pharma Inc.（Japan）
• Bausch Health Companies Inc.（Canada）
• Sumitomo Pharma America, Inc（U.S.）
• Reviva Pharmaceuticals Holdings, Inc.（U.S.）
• Acadia Pharmaceuticals Inc.（U.S.）
• VANDA PHARMACEUTICALS（U.S.）
• Eisai Co., Ltd.（Japan）
• Zydus Group（India）
• Lilly（U.S.）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Pfizer Inc.（U.S.）
• Bristol-Myers Squibb Company（U.S.）
• Mallinckrodt（U.S.）

結論と提言

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.88 billion in 2024 to USD 7.08 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

Market insights indicate a significant shift in the tardive dyskinesia treatment landscape, driven by the rising prevalence of psychiatric disorders and advancements in VMAT2 inhibitor therapies. The heightened regulatory support for accelerated approvals is fostering a favorable environment for treatment adoption. Increased awareness of tardive dyskinesia, particularly in regions with expanding healthcare infrastructure, is encouraging proactive management of this condition. Pharmaceutical companies are actively pursuing strategic partnerships to enhance research and development efforts. However, the market faces challenges, including high treatment costs, adverse effects associated with current therapies, and limited awareness in developing areas. Additionally, constrained R&D investments due to a smaller patient population may hinder widespread adoption of tardive dyskinesia treatments in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The global tardive dyskinesia (TD) treatment market is significantly driven by the supportive actions of regulatory bodies like the U.S. Food and Drug Administration (FDA), which have implemented expedited approval pathways for TD therapies in acknowledgment of the critical unmet medical needs. These initiatives, including fast-track designations and priority reviews, allow for a swifter market introduction of innovative treatments. This regulatory backing not only encourages pharmaceutical companies to focus their investments on developing medications for TD but also positively influences the overall outlook of the global tardive dyskinesia treatment market, fostering advancements in effective therapeutic options for patients.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces several constraints that hinder its growth potential. Despite the advancements brought by VMAT2 inhibitors in managing tardive dyskinesia (TD), these treatments are accompanied by adverse effects such as fatigue, depression, and somnolence, which can negatively influence patient adherence and overall quality of life. Consequently, some patients may choose to discontinue their treatment due to these side effects. Furthermore, apprehensions regarding the long-term safety profiles of these medications could lead healthcare providers to be cautious in prescribing them, ultimately slowing the widespread adoption of effective tardive dyskinesia therapies in the market.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend towards advanced VMAT2 inhibitor therapies, which have transformed the therapeutic landscape for this condition. Medications like valbenazine (Ingrezza) and deutetrabenazine (Austedo) have gained prominence due to their targeted approach in addressing the underlying mechanisms of tardive dyskinesia, resulting in enhanced efficacy and safety profiles compared to traditional treatments. The introduction of innovative formulations, such as Ingrezza Sprinkle, further supports treatment adherence among patients with swallowing difficulties. As research and development in this area continue to grow, advancements in VMAT2 inhibitors are expected to drive market expansion and shape treatment paradigms in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2025-2032)

• Market Overview
• Antipsychotics
• VMAT2 Inhibitors
• Botulinum Toxin
• Natural Remedies
• Dopamine-Depleting Medications
• Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2025-2032)

• North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Neurocrine Biosciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma America, Inc (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VANDA PHARMACEUTICALS (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations